This study was the first to screen COVID-19 patients with sepsis or at the edge of sepsis through the SOFA score and systematically reviewed the efficacy and safety of anti-cytokine therapy, such as specific IL-1, IL-6 inhibitors, and anti-GM-CSF in COVID-19 patients with organ dysfunction (SOFA ≥2). The gene discussed is CSF2; the disease is Sepsis.